These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18356312)

  • 1. Health technology assessment in the cost-disutility plane.
    Eckermann S; Briggs A; Willan AR
    Med Decis Making; 2008; 28(2):172-81. PubMed ID: 18356312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
    Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
    Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness acceptability curves--caveats quantified.
    Jakubczyk M; Kamiński B
    Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expected value of information and decision making in HTA.
    Eckermann S; Willan AR
    Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.
    Eckermann S; Willan AR
    Pharmacoeconomics; 2011 Jul; 29(7):563-77. PubMed ID: 21671686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
    Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
    Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Including quality attributes in efficiency measures consistent with net benefit: creating incentives for evidence based medicine in practice.
    Eckermann S; Coelli T
    Soc Sci Med; 2013 Jan; 76(1):159-68. PubMed ID: 23153543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin.
    Craig BA; Black MA
    Expert Rev Pharmacoecon Outcomes Res; 2001 Oct; 1(1):37-46. PubMed ID: 19807506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
    Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
    Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods.
    Groot Koerkamp B; Myriam Hunink MG; Stijnen T; Weinstein MC
    Health Econ; 2006 Apr; 15(4):383-92. PubMed ID: 16389669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Making health technology assessment information available for decision making: the development of a Thai database.
    Kapol N; Maitreemit P; Chalongsuk R; Amrumpai Y; Sribundit N; Thavorncharoensap M; Chaikledkaew U; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S8-10. PubMed ID: 19253482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis and formulary decision making in England: findings from research.
    Williams IP; Bryan S
    Soc Sci Med; 2007 Nov; 65(10):2116-29. PubMed ID: 17698271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health system and equity perspectives in health technology assessment.
    Hanvoravongchai P
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S74-87. PubMed ID: 19253490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility space.
    McCaffrey N; Agar M; Harlum J; Karnon J; Currow D; Eckermann S
    PLoS One; 2015; 10(3):e0115544. PubMed ID: 25751629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification of evidence in decision-analytic models of cost-effectiveness: a content analysis of published reports.
    Paisley S
    Int J Technol Assess Health Care; 2010 Oct; 26(4):458-62. PubMed ID: 20923588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The option value of delay in health technology assessment.
    Eckermann S; Willan AR
    Med Decis Making; 2008; 28(3):300-5. PubMed ID: 18480035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of clinical effects.
    Teerawattananon Y; Thavorncharoensap M; Mohara A
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S38-42. PubMed ID: 19253486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncertainty in cost-effectiveness analysis. Probabilistic uncertainty analysis and stochastic league tables.
    Baltussen RM; Hutubessy RC; Evans DB; Murray CJ
    Int J Technol Assess Health Care; 2002; 18(1):112-9. PubMed ID: 11987434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presenting results of probabilistic sensitivity analysis: the incremental benefit curve.
    Bala MV; Zarkin GA; Mauskopf J
    Health Econ; 2008 Mar; 17(3):435-40. PubMed ID: 17694580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.